SPDR S&P Biotech ETF $XBI Stock: Parkside Investments LLC Lowers Holdings

Parkside Investments LLC trimmed its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 4.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,303 shares of the exchange traded fund’s stock after selling 3,420 shares during the period. SPDR S&P Biotech ETF accounts for approximately 1.5% of Parkside Investments LLC’s investment portfolio, making the stock its 17th biggest position. Parkside Investments LLC owned approximately 0.12% of SPDR S&P Biotech ETF worth $12,978,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in XBI. Wealth Management Partners LLC acquired a new stake in SPDR S&P Biotech ETF in the 1st quarter valued at about $547,000. Ayalon Insurance Comp Ltd. grew its holdings in SPDR S&P Biotech ETF by 71.9% during the third quarter. Ayalon Insurance Comp Ltd. now owns 95,600 shares of the exchange traded fund’s stock worth $15,074,000 after purchasing an additional 40,000 shares during the period. Wellington Management Group LLP bought a new position in SPDR S&P Biotech ETF during the second quarter worth about $19,270,000. Continuum Advisory LLC increased its position in SPDR S&P Biotech ETF by 389.1% during the second quarter. Continuum Advisory LLC now owns 18,013 shares of the exchange traded fund’s stock worth $2,851,000 after buying an additional 14,330 shares during the last quarter. Finally, Syon Capital LLC increased its position in SPDR S&P Biotech ETF by 67.9% during the second quarter. Syon Capital LLC now owns 23,562 shares of the exchange traded fund’s stock worth $3,729,000 after buying an additional 9,530 shares during the last quarter.

SPDR S&P Biotech ETF Stock Up 3.6%

NYSEARCA:XBI opened at $153.24 on Wednesday. The stock’s 50 day moving average price is $157.79 and its two-hundred day moving average price is $147.39. The firm has a market capitalization of $10.58 billion, a price-to-earnings ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a 12-month low of $106.30 and a 12-month high of $169.89.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.